MUC16 and ovarian cancer: When ApoA1 was combined with CA125 and TTR, not only was a significant improvement observed in the overall sensitivity and specificity, but the panel was also sufficient for maximum discrimination between noncancer, stage I–II and all stages (I–IV) of ovarian cancer [103].